Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.59 |
| ▸ | PREP | P48147 | 1/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26094394 | 0.83 | DPP4 (0.59) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL858699 | 0.83 | DPP4 (0.59) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL5314581 | 0.83 | DPP4 (0.59) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL8253205 | 0.82 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL3344556 | 0.82 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL1239549 | 0.82 | DPP4 (0.62) | DPP4PREPDPP8DPP9 | |
| SCHEMBL5147875 | 0.82 | DPP4 (0.62) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL3398030 | 0.82 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL4465428 | 0.82 | DPP4 (0.62) | DPP4PREPDPP8DPP9 | |
| SCHEMBL8256353 | 0.82 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0937040-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 1999-08-25 | — | — | EP | claimed |
| WO-1998019998-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 1998-05-14 | — | — | WO | claimed |
| EP-1620396-B1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-8569250-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| EP-2247602-B1 | ADAMANTYL O-GLUCURONIDE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-20120295860-A1 | ORGANIC COMPOUNDS | HASSIEPEN ULRICH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-8252751-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| EP-2247602-A2 | ADAMANTYL O-GLUCURONIDE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20100256080-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| EP-1296974-B1 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009068531-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-6432969-B1 | NON-INSULIN DEPENDENT DIABETES, OBESITY, ARTHRITIS, AND OSTEOPOROSIS TREATMENT | NOVARTIS AG (CH) | 2002-08-13 | — | — | US | disclosed |
| WO-2001096295-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2001-12-20 | — | — | WO | disclosed |
| EP-1137635-A1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| US-6166063-A | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | NOVARTIS AG (CH) | 2000-12-26 | — | — | US | disclosed |
| US-6124305-A | TREATING NON-INSULIN DEPENDENT DIABETES MELLITUS | NOVARTIS AG (CH) | 2000-09-26 | — | — | US | disclosed |
| WO-2000034241-A1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2000-06-15 | — | — | WO | disclosed |
| US-6011155-A | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | NOVARTIS AG (CH) | 2000-01-04 | — | — | US | disclosed |
| EP-0937040-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998019998-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256080-A1 | ORGANIC COMPOUNDS | DPP4, DPP7, DPP3 | DPP4 1/4885PREP 800/4885DPP8 4/4885 |
| US-20120295860-A1 | ORGANIC COMPOUNDS | DPP4, DPP7, DPP3 | DPP4 1/4885PREP 803/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.